©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2015; 6(5): 99-103
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.99
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.99
Is there still a place for docetaxel rechallenge in prostate cancer?
Roberto Petrioli, Giandomenico Roviello, Medical Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy
Edoardo Francini, Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, 00161 Rome, Italy
Author contributions: Petrioli R and Roviello G contributed to study design and writing; Edoardo F contributed to writing.
Conflict-of-interest statement: No author has actual or potential conflicts of interest, including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could influence, or be perceived to influence, their work.
Correspondence to: Roberto Petrioli, MD, Medical Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Viale Bracci 11, 53100 Siena, Italy. r.petrioli@ao-siena.toscana.it
Telephone: +39-05-77586139 Fax: +39-05-77586231
Received: March 11, 2015
Peer-review started: March 18, 2015
First decision: June 3, 2015
Revised: June 15, 2015
Accepted: July 24, 2015
Article in press: July 27, 2015
Published online: October 10, 2015
Processing time: 216 Days and 9.9 Hours
Peer-review started: March 18, 2015
First decision: June 3, 2015
Revised: June 15, 2015
Accepted: July 24, 2015
Article in press: July 27, 2015
Published online: October 10, 2015
Processing time: 216 Days and 9.9 Hours
Core Tip
Core tip: New treatment options are currently available for metastatic castrate-resistant prostate cancer (mCRPC) patients after first-line chemotherapy with docetaxel. The actual role of docetaxel rechallenge in the evolving scenario of mCRPC treatment is discussed in this editorial.